Melanoma Immunotherapy

For over 30 years, dacarbazine was the only approved chemotherapy for metastatic melanoma, achieving response rates of just 10-15% with no survival benefit. High-dose IL-2 offered durable responses in a small minority (6-8%) but at the cost of severe toxicity requiring ICU-level monitoring. The discovery that CTLA-4 functioned as an immune checkpoint — a brake on T-cell activation — by James Allison provided the conceptual breakthrough that tumors could be fought by unleashing the immune system rather than directly targeting cancer cells. Early phase I/II trials of ipilimumab (anti-CTLA-4) showed unprecedented durable responses in some patients, suggesting a fundamentally new treatment paradigm.

The 2010 landmark trial by Hodi et al. demonstrated that ipilimumab improved median overall survival from 6.4 to 10.1 months in previously treated metastatic melanoma — the first agent ever to extend survival in this disease. Critically, the Kaplan-Meier curves showed a plateau at approximately 20%, suggesting durable long-term survival in a subset of patients, a phenomenon never seen with chemotherapy. The subsequent CheckMate 066 and KEYNOTE-006 trials proved that PD-1 inhibitors (nivolumab and pembrolizumab) were superior to both ipilimumab and chemotherapy, achieving objective response rates of 40-44% with far fewer immune-related adverse events. These results established PD-1 blockade as the backbone of melanoma immunotherapy and earned James Allison and Tasuku Honjo the 2018 Nobel Prize in Medicine.

CheckMate 067 established the combination of nivolumab plus ipilimumab as the most effective immunotherapy regimen, achieving a 5-year overall survival rate of 52% in metastatic melanoma — a disease with a historical median survival of 6-9 months. The combination came at the cost of grade 3-4 immune-related adverse events in 59% of patients, but landmark 6.5-year follow-up data confirmed unprecedented durability. Immunotherapy then moved earlier in the disease course: CheckMate 238, KEYNOTE-054, and KEYNOTE-716 demonstrated adjuvant nivolumab and pembrolizumab significantly reduced recurrence in resected stage III-IV melanoma. Most recently, the SWOG S1801 and NADINA trials showed that neoadjuvant immunotherapy before surgery achieves pathological complete response rates of 25-60%, potentially revolutionizing the surgical approach to resectable melanoma.

NCCN, ESMO, and Australian guidelines now recommend PD-1 inhibitor monotherapy or nivolumab-ipilimumab combination as first-line therapy for unresectable/metastatic melanoma. Adjuvant immunotherapy with pembrolizumab or nivolumab is standard of care for resected stage IIB-IV melanoma. The NCCN 2024 guidelines incorporated neoadjuvant immunotherapy as a preferred approach for clinically apparent stage III disease. BRAF-mutant melanoma has the additional option of targeted therapy (dabrafenib-trametinib), though immunotherapy is generally preferred first-line for its durability potential.

Melanoma immunotherapy in 2025-2026 represents arguably the greatest oncological success story of the 21st century. Five-year survival for metastatic melanoma has risen from under 10% to over 50% with combination immunotherapy. The neoadjuvant paradigm is reshaping surgical practice, with pathological complete response potentially guiding de-escalation of surgery and adjuvant therapy. Novel combinations (anti-LAG-3 with relatlimab, KEYNOTE-D36 lifileucel TIL therapy) are expanding options for checkpoint-refractory disease. Biomarker development (TMB, PD-L1, gene expression profiling) aims to personalize treatment selection, though no single biomarker reliably predicts immunotherapy response. The field is now focused on curing more patients and reducing the toxicity burden of combination regimens.